您的位置: 首页 > 农业专利 > 详情页

NK CELL-ACTIVATING FUSION PROTEIN, NK CELL, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
专利权人:
KOREA RESEARCH INSTUTE OF BIOSCIENCE AND BIOTECHNOLOGY
发明人:
Seok Ho Kim,Jaemin Lee,Duck Cho
申请号:
US16500051
公开号:
US20200148786A1
申请日:
2018.04.05
申请国别(地区):
US
年份:
2020
代理人:
摘要:
The present invention relates to a fusion protein for cancer treatment and a use thereof.The fusion protein for preventing or treating cancer of the present invention comprises a fusion polypeptide comprising: an antibody or fragment thereof binding to a tumor-associated antigen; a linker; and a NK cell-inducing protein of CXCL16, wherein a co-administration of the fusion polypeptide along with the NK cells, an immunocyte therapeutic agent, greatly increases an influx of the NK cells into cancer expressing a certain antigen, thereby having a remarkable effect on preventing or treating cancer.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充